Institution
Mahidol University
Education•Bangkok, Nakhon Pathom, Thailand•
About: Mahidol University is a education organization based out in Bangkok, Nakhon Pathom, Thailand. It is known for research contribution in the topics: Population & Malaria. The organization has 23758 authors who have published 39761 publications receiving 878781 citations.
Topics: Population, Malaria, Plasmodium falciparum, Medicine, Plasmodium vivax
Papers published on a yearly basis
Papers
More filters
University of Sydney1, The Chinese University of Hong Kong2, Shanghai Jiao Tong University3, Kurume University4, Yonsei University5, Wenzhou Medical College6, Mansoura University7, Marmara University8, University of Indonesia9, Bangabandhu Sheikh Mujib Medical University10, National University of Singapore11, National Taiwan University12, Aga Khan University13, University of Malaya14, Mahidol University15, University of Western Australia16, University of Tokyo17
TL;DR: The clinical practice guidelines of the Asian Pacific Association for the Study of the Liver on MAFLD are presented to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data.
Abstract: Metabolic associated fatty liver disease (MAFLD) is the principal worldwide cause of liver disease and affects nearly a quarter of the global population. The objective of this work was to present the clinical practice guidelines of the Asian Pacific Association for the Study of the Liver (APASL) on MAFLD. The guidelines cover various aspects of MAFLD including its epidemiology, diagnosis, screening, assessment, and treatment. The document is intended for practical use and for setting the stage for advancing clinical practice, knowledge, and research of MAFLD in adults, with specific reference to special groups as necessary. The guidelines also seek to improve patient care and awareness of the disease and assist stakeholders in the decision-making process by providing evidence-based data. The guidelines take into consideration the burden of clinical management for the healthcare sector.
361 citations
TL;DR: P. vivax malaria during pregnancy is associated with maternal anaemia and low birthweight, and antimalarial prophylaxis against P.vivax in pregnancy may be justified.
360 citations
National and Kapodistrian University of Athens1, Gunma University2, University of Manchester3, University of Wisconsin-Madison4, University of Southampton5, The Chinese University of Hong Kong6, University of Cape Town7, Swiss Institute of Allergy and Asthma Research8, Washington University in St. Louis9, University of Padua10, National University of Singapore11, Paris Descartes University12, University of Verona13, Duke University14, Creighton University15, Pontifical Catholic University of Chile16, Ain Shams University17, National Health Service18, Medical University of Vienna19, Karolinska Institutet20, University of Virginia21, University of Ulsan22, Chang Gung University23, Stellenbosch University24, Medical University of Łódź25, Charité26, University of South Florida27, Sungkyunkwan University28, University of Colorado Denver29, Nippon Medical School30, Charles University in Prague31, Children's Memorial Hospital32, Royal Children's Hospital33, Federal University of Paraná34, Children's Mercy Hospital35, University of Queensland36, Pontifícia Universidade Católica do Rio Grande do Sul37, Princess Margaret Hospital for Children38, University of Denver39, University of Turku40, Mahidol University41, Nova Southeastern University42, University of Gothenburg43, University of Zurich44, Kaiser Permanente45
TL;DR: The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference.
Abstract: Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.
360 citations
Memorial Sloan Kettering Cancer Center1, Pontifícia Universidade Católica do Rio Grande do Sul2, Seoul National University3, Mahidol University4, Queen Elizabeth II Hospital5, University of Modena and Reggio Emilia6, University of Colorado Denver7, University of Nottingham8, Novartis9, University of Toronto10
TL;DR: The trial results support the standard treatment paradigm of first-line sunitinib followed by everolimus at progression, and Everolimus did not demonstrate noninferiority compared with sunit inib as a first- line therapy.
Abstract: Purpose A multicenter, randomized phase II trial, RECORD-3, was conducted to compare first-line everolimus followed by sunitinib at progression with the standard sequence of first-line sunitinib followed by everolimus in patients with metastatic renal cell carcinoma. Patients and Methods RECORD-3 used a crossover treatment design. The primary objective was to assess progression-free survival (PFS) noninferiority of first-line everolimus compared with first-line sunitinib. Secondary end points included combined PFS for each sequence, overall survival (OS), and safety. Results Of 471 enrolled patients, 238 were randomly assigned to first-line everolimus followed by sunitinib, and 233 were randomly assigned to first-line sunitinib followed by everolimus. The primary end point was not met; the median PFS was 7.9 months for first-line everolimus and 10.7 months for first-line sunitinib (hazard ratio [HR], 1.4; 95% CI, 1.2 to 1.8). Among patients who discontinued first-line, 108 (45%) crossed over from everolim...
359 citations
University of Texas MD Anderson Cancer Center1, Federal University of Paraná2, University of São Paulo3, University of Paris4, Mahidol University5, Medical University of Łódź6, Gdańsk Medical University7, Fred Hutchinson Cancer Research Center8, Bristol-Myers Squibb9, University of California, San Francisco10
TL;DR: Dasatinib represents a safe and effective therapy for CP-CML resistant to conventional imatinib doses with improved cytogenetic and molecular response rates and progression-free survival relative to high-dose Imatinib.
359 citations
Authors
Showing all 23819 results
| Name | H-index | Papers | Citations |
|---|---|---|---|
| Nicholas J. White | 161 | 1352 | 104539 |
| Pete Smith | 156 | 2464 | 138819 |
| Randal J. Kaufman | 140 | 491 | 79527 |
| Kevin Marsh | 128 | 567 | 55356 |
| Barry M. Trost | 124 | 1635 | 79501 |
| John R. Perfect | 119 | 573 | 52325 |
| Jon Clardy | 116 | 983 | 56617 |
| François Nosten | 114 | 777 | 50823 |
| Paul Turner | 114 | 1099 | 61390 |
| Paul Kubes | 109 | 393 | 41022 |
| Ian M. Adcock | 107 | 660 | 42380 |
| Peter H. Verburg | 107 | 464 | 34254 |
| Guozhong Cao | 104 | 694 | 41625 |
| Carol L. Shields | 102 | 1424 | 46800 |
| Nicholas P. J. Day | 102 | 708 | 50588 |